logo-loader
viewImugene Ltd

Imugene will present lead candidate HER-Vaxx at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about the significance of presenting the clinical stage immuno-oncology company's lead candidate - the HER-Vaxx cancer vaccine - at the upcoming American Association for Cancer Research 2019 Annual Meeting.

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Quick facts: Imugene Ltd

Price: 0.035 AUD

ASX:IMU
Market: ASX
Market Cap: $154.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read